Skip to main content
SpringerLink
Log in

Oral L-arginine can reverse digital necrosis in Raynaud's phenomenon

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Raynaud's phenomenon is characterized by transient reduction in blood supply through the small arteries in the hands and feet. Severe Raynaud's phenomenon can cause digital necrosis. It has been hypothesized that nitric oxide may have a role in Raynaud's phenomenon. We report two cases in which oral L-arginine reversed digital necrosis in Raynaud's phenomenon and two additional cases in which the symptoms of severe Raynaud's phenomenon were improved with oral L-arginine. These reports suggest that a defect in nitric oxide synthesis or metabolism is present in Raynaud's phenomenon. They also suggest a potential role for oral L-arginine therapy in Raynaud's phenomenon, especially in Raynaud's phenomenon with digital necrosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lewis T: Experiments relating to the peripheral mechanisms involved in the spasmodic arrest of the circulation in the fingers, a variety of Raynaud's disease. Heart 15: 7-99, 1929

    Google Scholar 

  2. Belch JJ: Raynaud's phenomenon. Cardiovasc Res 33: 25-30, 1997

    Google Scholar 

  3. Chen XL, Rembold CM: Nitroglycerin relaxes rat tail artery primarily by lowering Ca2+ sensitivity and partially by repolarization. Am J Physiol Heart Circ Physiol 271: H962-H968, 1996

    Google Scholar 

  4. Rembold CM, Foster B, Strauss JD, Wingard CJ, Van Eyk JE: cGMP mediated phosphorylation of heat shock protein 20 may cause smooth muscle relaxation without myosin light chain dephosphorylation. J Physiol (Lond) 524: 865-878, 2000

    Google Scholar 

  5. Murad F: Regulation of cytosolic guanylyl cyclase by nitric oxide: the NO-cyclic GMP signal transduction system. Adv Pharmacol 26: 19-33, 1994

    Google Scholar 

  6. Khan F, Litchfield SJ, McLaren M, Veale DJ, Littleford RC, Belch JJ: Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon. Arth Rheum 40: 352-357, 1997

    Google Scholar 

  7. Khan F, Belch JJ: Skin blood flow in patients with systemic sclerosis and Raynaud's phenomenon: Effects of oral L-arginine supplementation. J Rheumatol 26: 2389-2394, 1999

    Google Scholar 

  8. Singh S, De Trafford JC, Baskerville PA, Martin JF: Response of digital arteries to endothelium dependent and independent vasodilators in patients with Raynaud's phenomenon. Eur J Clin Invest 25: 182-185, 1995

    Google Scholar 

  9. Freedman RR, Girgis R, Mayes MD: Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma (letter). Lancet 28: 354-739, 1999

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Division, Departments of Internal Medicine and Physiology, University of Virginia Health System, Charlottesville, VA, 22908, USA

    Christopher M. Rembold & Carlos R. Ayers

Authors
  1. Christopher M. Rembold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlos R. Ayers
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rembold, C.M., Ayers, C.R. Oral L-arginine can reverse digital necrosis in Raynaud's phenomenon. Mol Cell Biochem 244, 139–141 (2003). https://doi.org/10.1023/A:1022422932108

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1022422932108

Search

Navigation